Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Segezha Group reported for Q1 2023 by RAS

4/18/23 SGZH

Board of Directors of Perm Energy Supply Company recommended that dividends be paid for 2022

4/17/23 PMSB

Globaltruck reported for 2022 according to IFRS

4/17/23 GTRK

Inter RAO began exporting electricity to Kyrgyzstan for the first time

4/17/23 IRAO

UEC signed a contract for 1,000 hoppers for grain transportation

4/17/23 UWGN

Yandex is testing a cab service in Guatemala

4/17/23 YNDX

MTS has entered the capital of the developer of IoT solutions for transport Project Environment

4/17/23 MTSS

Rosinter Restaurants Holding reports for 2022 according to IFRS

4/17/23 ROST

X5 Retail Group opened a production of ready-made food in St. Petersburg

4/17/23 FIVE

Yandex launches video translation from Chinese

4/17/23 YNDX